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Abstract  
The HIV-1 viral protein U (Vpu) and protease play a pivotal role in the infectious lifecycle of human immunodeficiency 
virus-1. The objective of this study is to find the degree of conservation of the viral protein U (Vpu) and protease protein 
and to detect conserved binding sites, which might be used as target sites for potential anti-Vpu and anti-protease drugs. 
The conservation analysis was based on 4231 amino acid sequences for Vpu and 13,457 amino acid sequences for 
protease. The conservation analysis revealed a number of conserved and variable residues. The universally conserved 
residues identified in this study might be involved in either structure stabilizing or protein-protein interactions. The novel 
conserved potential binding sites which have been identified are: Vpu (Ile39, Arg45, Ile46 and Gly71) and protease (Pro9, 
Thr80 and Asn83). Along with conservational analysis, structural analysis revealed novel binding sites, namely four 
conserved sites on Vpu (Arg49, Ala50, Ser53, Gly54, Gly59; Glu56, Ser57, Asp60; Glu56, Gly71; Glu48, Glu51, Asp52, 
Gly54-Glu56) and single novel conserved site on protease (Thr4, Trp6 and Arg87, Asn88, Thr91, Gln92). The outcome of 
this study provides the basis for developing anti-Vpu and anti-protease drugs which have abridged potential to induce drug 
resistance through mutations. 
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Introduction  
Acquired immunodeficiency syndrome (AIDS) is caused by the infectious agent human 
immunodeficiency virus (HIV), affecting estimated 2.5 million people and results in 1.5 million 
deaths in the year 2014 [1]. In the past few years, owing to substantial rise in the usage of 
anti-retroviral therapy, there has been a stable decline in the AIDS associated deaths [1].There are 
two types of HIV namely, human immunodeficiency virus type 1 (HIV-1) and human 
immunodeficiency virus type 2 (HIV-2) [2, 3]. Since the discovery of HIV-1 (which was way back 
in 1983) up till now, HIV-1 remains to be the foremost concern regarding public health globally [4]. 
By realizing the devastating nature of HIV, the researchers globally are unified to uncover 
solutions which will facilitate in fighting this elusive virus. As a result of strong and determined 
efforts, the highly active antiretroviral therapy (HAART) was developed [5-7]. HAART has 
drastically improved and raised the lifespan of patients affected with HIV; yet it is unable to 
eradicate the virus totally from the HIV patients. This is down to the fact that infected cells are 
resistant to the apoptosis which is bestowed by the HIV.Without eliminating these cells it is 
impractical to eradicate the virus absolutely from an infected individual. Therefore is of urgent 
importance to develop antiretroviral drugs against those proteins which are accountable for 
conferring apoptosis resistance to the infected cell. 
HIV-1 is a RNA virus which belong to lentivirus class of retrovirus, whose genome encodes 
three structural proteins (gag, pol and env), two regulatory proteins (tat and rev) and four accessory 
proteins (vpu, vif, nef and vpr) [8, 9]. The viral protein U (Vpu) is a 16 KDa trans-membrane 
protein and is about 81 amino acids long [10]. Vpu is known to exist as tetramer, pentamer and 
hexamer [11]. The Vpu monomer is predicted to have three domains namely, N-terminal domain 
(NTD; residues 1-3; extra-cellular), transmembrane domain (TD; residues 4-27) and C-terminal 
domain (CTD; residues 28-81; intracellular) [12, 13]. The multiple roles of Vpu identified are: (i) 
CD4 degradation via proteasome pathway [14, 15] (ii) elevate the release of virion progeny from 
the infected cells via inhibition of tetherin[16, 17] (iii) down regulation of major histocompatibility 
complex I and major histocompatibility complex II [18, 19] (iv) hindrance in degranulation of 
natural killer cells by down regulating the natural killer-T and B cell antigen [20] (v) down 
regulation of poliovirus receptor activating ligand of natural killer cells [21] (vii) modulation of 
CD1d [22, 23] (vii) promotes apoptosis, mediated by p53 [24].  
The HIV-1 protease (MW= 10.7 KDa) is a constituent of aspartic protease family of about 99 
amino acid residues long [25]. The essential function of HIV-1 protease is to cleave the peptide 
bonds in the polyproteins of gag and pol genes during the maturation process of virus [25-28]. 
HIV-1 protease exists as a homodimer with identical contribution of catalytic residues from both 
the subunits to the active site [29, 30]. The active site of the protease consists of two triads 
composing of Asp25-Thr26-Gly27 contributed by the two subunits [29, 30]. The active site is gated 
by an extended beta hairpin loop known as flaps; the region corresponding to the flaps is residues 
46-56 [29, 30]. The two subunits of the protein are joined by the non-covalent interactions between 
N-terminal (residues 1-5) and C-terminal (residues 95-99) residues and these interactions are 
important in dimer stability [31]. 
The emergence of HIV-1 mutants which are drug resistant and the spreading of these mutants 
globally are serious cause of concern. To overcome this problem one has to exploit HIV-1 proteins 
as a potential drug targets. In order to achieve this target one has to understand the conservation 
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pattern of these proteins. At present, there are no licensed drugs available targeting the Vpu protein 
of HIV-1. There are many licensed drugs available which target the protease; they are saquinavir, 
Ritonavir, Indinavir, nelfinavir, Amprenavir, fosamprenavir, Lopinavir, atazanavir, Tipranavir and 
darunavir[32]. There are some promising compounds at clinical trials stage, which are PL-100, 
Brecanavir, SPI-256 and GS 8374 [32]. But the main problem with the above said drugs are that these 
drugs get ineffective as a result of mutations in the HIV-1 protease. To overcome this problem one 
has to exploit the conserved residues in the HIV-1 protease. The aims of this study are to identify 
the degree of conservation of Vpu and protease proteins to facilitate the detection of regions with 
universal conservation. By mapping the obtained conservational scores on to the protein structure 
in conjunction with binding site analysis suggests binding sites for antiviral compounds which are 
resistant to mutations that may arise in the future.  
Methods  
Sequence analysis and protein structure  
The full length sequences of the Vpu protein were obtained from UniProt[33] belonging to all the 
HIV-1 subtypes were selected. For alignment of the collected proteins sequences, MUSCLE 
version 3.8 [34] was used with default parameters. Multiple refinements of the obtained alignment 
were carried out resulting in 26-30 iterations, until no further improvement was attained. The 
structures of Vpu protein (residues 7-25 and residues 37-81) and protease protein (residues 1-99) 
were obtained from Protein Data Bank (PDB) [35] with the entries 1PI8 [36]; 1VPU [37] and 
3GGX [38] respectively.  
Conservation analysis 
By providing multiple sequence alignment and protein structure file as an input, conserved regions 
were identified and mapped onto the experimental protein structures using ConSurf server 
(http://consurf.tau.ac.il/) [39-42]. By taking evolutionary relationships among protein sequences 
into account, ConSurf algorithm produces consequential conservation scores. ConSurf algorithm 
gives more emphasis to those protein sequences which are evolutionarily distant, thus producing 
conservation scores which are significant [39-42]. The ensuing conservation scores are criterion 
scores with an average of 0 and a standard deviation of 1. The residues with score < 0 denote higher 
conservation and those with score >0 are variable residues [39-42].The Bayesian algorithm is used 
to evaluate the confidence intervals of calculated conservation scores [39-42]. The conservation 
score given by ConSurf server is divided into scale of nine grades which are given for the purpose 
of visualization [39-42]. Most variable positions are placed in grade one (turquoise), intermediately 
conserved positions are placed in grade five (white), and most conserved positions are placed in 
grade nine (maroon) [39-42].  
Binding site analysis 
Ligand binding sites (LBS) on Vpu protein structure were identified using COFACTOR 
(http://zhanglab.ccmb.med.umichedu/COFACTOR/), identifies the LBS using both global and local 
with templates from PDB and match local motifs of the identified template with that of query 
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structure [43-45]; TM-site (http://zhanglab.ccmb.med.umich.edu/COACH/), identifies the LBS 
using intermediary approach if both local and global alignments [45, 46]; 
S-site(http://zhanglab.ccmb.med.umich.edu/COACH/), identifies the LBS by explicitly comparing 
binding site specific sequence profiles [45, 46]and SiteHound 
(http://scbx.mssm.edu/sitehound/sitehound-web/Input.html) which uses energy based method to 
find regions with high potential for ligand interactions [47].  
Results  
Multiple alignments of protein sequences and Vpu protein structure 
For the HIV-1 Vpu protein, 4231 sequences and for the protease protein 13,457 sequences were 
obtained from UniProt [33]. None of the templates identified in the Protein Data Bank (PDB) [35] 
has covered the entire Vpu protein. The region between the residues Leu7-Ile25 and Arg37-Leu81 
of the Vpu are the only ones whose structures are experimentally solved. The experimental 
structure for the fragment Leu7-Ile25 consists of a single • -helix which is part of transmembrane 
domain of Vpu. The experimental structure for the fragment Arg37-Leu81 consists of four 
• -helices: helix 1 (39-49), helix 2 (53-55), helix 3 (60-63) and helix 4 (75-78); which are connected 
by loops. The obtained experimental structure (residues 1-99 amino acids) consists of eleven 
• -sheets (residues 1-3; 9-15; 18-25; 30-35; 43-47; 54-59; 62-67; 69-73; 75-78; 83-86 and 96-99) 
which are numbered sequentially and a lone • -helix (residues 87-92). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 The conservation obtained by projecting conservation scores on to the ribbon structure of the Vpu protein 
(A) and the residue conservation of the Vpu protein obtained from ConSurf server [39-42]. 
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Conserved and variable residues 
The variable and conserved residues in the Vpu and protease proteins were identified using 
ConSurf server [39-42] and are illustrated in Figure 1 and Figure 2. The variable residues of grades 
1-3 and conserved residues of grades 7-9 are clustered together in Table 1. The conservation scores 
were projected onto the Backbone ribbon structures of the Vpu protein and protease protein and are 
shown in Figure 1 and Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 The conservation obtained by projecting conservation scores on to the ribbon structure of the protease 
protein (A) and the residue conservation of the protease protein obtained from ConSurf server [39-42]. 
 
 
Table 1 Variable and conserved residues of Vpu and protease proteins of HIV-1 identified using the ConSurf server 
[39-42]. 
 
Residues Viral protein U Protease  
Conserved 
(grades 7-9) 
Met1, Ile6, Ile9, Ala11, Leu12, Val14, Ile17, 
Ala19, Ile20, Val22, Trp23, Ile25, Val26, 
Ile28, Glu29, Gln36, Ile39, Asp40, Arg45, 
Ile46, Glu48-Ser57, Gly59, Asp60, Glu63, 
Leu64, Gly71, Ala74, Asp80 
Pro1-Pro9, Val11, Gly17, Glu21-Val32, Glu34, 
Leu38, Gly40, Trp42, Pro44, Lys45, Ile47, 
Gly49-Gly52, Lys55, Val56, Gln58, Tyr59, 
Glu65, Ile66, Gly68, Val75, Leu76, Gly78-Pro81, 
Asn83, Ile85-Asn88, Thr91, Gln92, Gly94, 
Thr96- Phe99 
Variable 
(grades 1-3) 
Gln2, Ser3, Glu5, Leu7, Ala16, Ile18, Phe27, 
Tyr30, Leu34, Arg35, Asp44, Arg47, Glu58, 
Ala66, His73, Asp77, Asp79 
Leu10, Thr12-Gly16, Leu19,Lys20, Leu33, 
Glu35-Ser37, Arg41, Met46, Arg57, Asp60, 
Ile62- Ile64, Cys67, His69, Lys70-Gly73, Val77, 
Val82, Leu89, Leu90, Ile93 
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Conservation scores for the Vpu protein were obtained between -0.929 (maximum conservation) 
and 3.782 (maximum variability) by the ConSurf server [39-42]. In general the Vpu protein is 
conserved with approximately 45.7% of the residues belong to grades 7-9 (conserved), while 21% 
of the residues belong to grades 1-3 (variable). Altogether, eighteen residue positions 
(approximately 22.3% of total residues) were found to be highly conserved (grade 9) and are shown 
in the Table 1. The residue positions 1, 53, 55 and 57 showed highest conservation among all the 
sequences analysed. In total, nine residues (11.2% of total residues) were found to be highly 
variable (grade 1). The residue positions 5, 7, and 27 showed highest variation among all the 
sequences analysed.      
The transmembrane • -helix (Leu7-Ile25) was found to be intermediately conserved, with 
residues Ile20, Val22 and Trp23 were found to be highly conserved (grade 9). The • -helix 1 of the 
CTD fragment was found to be intermediately conserved with about 55% conservation. Residues 
Ile39, Arg45, Ile46 and Arg49 were found to be highly conserved (grade 9), while residues Asp40 
and Glu48 were found to be conserved (grade 7). The second • -helix was found to be highly 
conserved with residues Ser53, Gly54 and Asn55 belong to grade 9. The third • -helix was found to 
be intermediately conserved with Asp60 (grade 9) andGlu63 (grade 7) were only residues to be 
found conserved. The fourth • -helix was also found to be variable with its residue either in grade 3 
or grade 4. The loop joining the • -helix 1 and • -helix 2 was found to be highly conserved, while the 
loop joining the • -helix 2 and • -helix 3 was found to be conserved. The loop joining the • -helix 3 
and • -helix 4 was found to be variable. Apart from the conserved residues in the known functional 
regions of Vpu, novel highly conserved residues were identified, namely Ile39, Arg45, Ile46 and 
Gly71.  
Conservation scores for the protease protein were obtained between -0.770 (maximum 
conservation) and 5.304 (maximum variability) by the ConSurf server [39-42]. In general the 
protease protein is conserved with approximately 61% of the residues belong to grades 7-9 
(conserved), while 31.1% of the residues belong to grades 1-3 (variable).Altogether, forty one 
residue positions (approximately 41% of total residues) were found to be highly conserved (grade 9) 
and are shown in the Table 1. The residue positions 1, 9, 26-29, 31, 44, 56, 80 and 83 showed 
highest conservation among all the sequences analysed. In total, twenty two residues (20.5% of 
total residues) were found to be highly variable (grade 1). The residue positions 10, 19, 37 and 63 
showed highest variation among all the sequences analysed.      
The conservation analysis of protease protein revealed a pattern in residue conservation across 
its secondary structures. The • -sheet 1 and • -sheet 11 were found to be highly conserved, whereas 
• -sheet 8 was found to be highly variable. The • -sheet 3, • -sheet9 and • -sheet 10 showed similar 
level of amino acid conservation where as residue conservation of • -sheet 4, • -sheet 5 and • -sheet 
6 were alike. A very low amount of residue conservation was observed in the • -sheet 2 and • -sheet 
7. The loop 1, loop 3 and loop 8 were found to be completely conserved, while loop 7 and loop 9 
were found to be variable. Intermediate conservation was observed in the loop 2 and loop 11, 
whereas loop 5 and loop 10 were found to be mostly conserved. The lone • -helix showed moderate 
level of conservation among its amino acid residues. 
Small molecule binding potential 
One of the important objectives of the present study was to detect potential drug binding sites 
which are spatially in close proximity to the conserved regions. Putative ligand binding sites were 
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identified using COFACTOR (detects LBS by global and local alignments with template structures 
in PDB), TM-site (detects LBS by transitional approach balancing global and local alignments), 
S-site (detects LBS by comparing sequence profiles which are binding site specific) and SiteHound 
(detects LBS by positive interaction between a chemical probe and protein structure) algorithms 
[43-47].By amalgamating the binding site results with that of evolutionary analysis, binding sites 
which are in the regions of conservation were identified on both Vpu and protease proteins which 
are shown in Table 2.  
 
Table 2The putative conserved ligand binding sites identified on Vpu and protease protein using COFACTOR, 
TM-site, S-site and SiteHound algorithms [43-47]. 
 
Site 
Binding sites located in conserved regions of Vpu 
protein 
Binding sites located in conserved regions of protease 
protein 
1 Arg49, Ala50, Ser53, Gly54, Gly59 Asp25, Gly27, Asp29, Asp30, Val32, Gly49, Ile50, Pro81 
2 Glu56, Ser57, Asp60 Asp25, Gly27, Gly49, Ile50 
3 Glu56, Gly71 Thr4, Trp6 
4 Glu51, Asp52 
Leu5, Trp6, Gln7, Arg8, Pro9, Leu23, Leu24, Asp25, Thr26, 
Gly27 
5 Glu48, Glu51, Asp52, Gly54, Asn55,Glu56 Ala28, Asp29, Asp30, Ile47 
6 Ile46, Arg49 Gln2,Ile3, Thr4, Leu5, Trp6, Gln7 
7 Asp60, Glu63 Pro1, Gln2, Ile3, Thr96, Leu97, Asn98, Phe99 
8 Glu48, Glu51 Arg87, Asn88, Thr91, Gln92 
9 Arg45, Glu48  
    Note: Conserved residues (grade 7-8) are shown in bold face while highly conserved    
residues (grade 9) are shown in bold face and underlined.  
In total nine potential binding sites with high conservation were found on the HIV-1 Vpu protein. 
Binding sites 1 to 9 are located in the conserved regions. Site 4 and site 6 are found to be highly 
conserved, while site 1, site 2, site 5 and site 7 were found to contain highly conserved residues. In 
total eight potential binding sites with high conservation were found on the HIV-1 protease. Highly 
conserved sites were found in close proximity to the active site, namely site 1, site 2, site 4 and site 
5. Conserved sites namely, site 3, site 6 and site 7 are found to be located in the region which is 
involved in non-covalent interactions. Binding site 8 is located in close proximity to the region 
which is important in the formation of the dimer.   
Discussion  
Sequence conservation 
The objective of the present study was to determine the degree of conservation of the Vpu protein 
among all the subtypes of human immunodeficiency viruses. The Vpu and protease proteins from 
all subtypes were analyzed together to facilitate the identification of universally conserved residues 
of potential pandemic HIV viruses that might arise in future due to either a event of mutation. The 
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conserved residues detected on the Vpu and protease proteins may have either functional 
importance or structural importance [48]. On the contrary, variable sites arise as a result of either 
adaptation or evolutionary pressure to evade the host immune system [48].  
In the regions which are responsible for the differential ability of Vpu belonging to HIV-1 and 
simian immunodeficiency virus-chimpanzee (residues 1-8 and 14-22) [49], residues Met1, Ile20 
and Val22 were found to be highly conserved (grade 9), while residues Ile6, Val14, Ile17 and 
Ala19 were found to be conserved (grades 7-8). Likewise in the region which is recognised by beta 
transducing repeat-containing protein (residues 52-57) [50], except Glu56 which was found to be 
conserved (grade 8), all the other residues were found to be highly conserved (grade 9). The regions 
which are assigned for trafficking signals (residues 29-34 and residues 63-68) [51, 52], residues 
Glu29 and Glu63 were found to be conserved (grades 7-8), while residue Leu64 was found to be 
highly conserved (grade 9). Amino acid residues which were found to be critical in the interaction 
between Vpu and tetherin proteins (residues 11, 14-16, 18, 22, 26-28, 34, 37 and 41) [53-55], 
residues Ala11, Val14, Val26 and Ile28 were found to be conserved residues (grades 7-8), while 
residue Val22 was found to be highly conserved. 
In the functionally important regions of HIV-1 protease, high residual conservation was found. 
In the regions (1-5 and 95-99) which are important in the formation and maintaining the stability of 
the dimer, residues Pro1, Gln2, Thr4, Leu5, Thr96, Leu97 and Asn98 were found to be highly 
conserved (grade 9), while residues Ile3 and Phe99 were found to be conserved (grade 8). The 
active site triad residues (Asp25, Thr26 and Gly27) were found to be highly conserved (grade 9). In 
the flap region which gates the active site of the protease, residues Ile47, Gly49, Ile50, Gly51, 
Gly52 and Val56 were found to be highly conserved (grade 9), while residue Lys55 was found to be 
assigned to grade 7 (conserved). Apart from the residues with highest conservation in the known 
functional region, novel highly conserved residues elsewhere in the protein were detected, namely 
Pro9, Thr80 and Asn83. These residues with highest conservation might have functional or 
structural importance which is currently not known.   
Small molecule binding potential 
Most of the predicted LBS identified on the Vpu and protease proteins are surrounded by conserved 
residues. Targeting these LBS using small drug molecule will most probably result in disruption of 
Vpu and protease function. Among the predicted binding sites identified by different methods, few 
novel binding sites were detected on both the proteins. These novel sites may be either involved in 
new protein-protein interactions or sites of known protein-protein interactions.  
The novel binding sites identified on Vpu protein are binding site 1 to binding site 9. These novel 
sites are completely conserved. Targeting these sites using small ligand molecule would inhibit the 
functions of the Vpu protein. These sites might be functionally important which can be explained 
by the degree of conservation found in these sites and the functions of these sites are not elucidated 
yet.  
In order to significantly inhibit the main activity of the HIV-1 protease that is cleavage of the 
peptide bonds in the polyproteins of gag and pol genes, binding sites- site 1, site 2, site 5 and site 6 
should be targeted with small drug like molecules. Upon binding to these sites, these drug 
molecules either inhibit the ligand binding to the active site or induce a conformational change in 
the structure of the protein such that the protein is rendered useless. The HIV-1 protease is known 
to be functional only in the dimer state that is homodimer, to inhibit the protein from forming dimer 
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binding sites: site3, site 7, site 8 and site 9 should be targeted with small drug like organic 
molecules. After binding to these sites, the drug molecules will inhibit the formation of 
non-covalent interactions between the residues which leads to dissociation of the two homomer. 
More over by targeting the binding sites identified in this study, it is highly unlikely that the drugs 
will become ineffective by an event of mutation in the HIV-1 protease that may arise in the future.  
Conclusion  
In conclusion the study of 4231 Vpu protein sequences and 13,457 protease protein sequences 
divulge an elevated level of sequence conservation pattern that intersects with prospective ligand 
binding site analysis rendering the Vpu and protease proteins as an exceptional drug target. 
Targeting the conserved binding sites identified in this study using small drug molecule will 
effectively diminish the activity of the both the proteins. Moreover, anti-Vpu and anti-protease 
drugs targeting these conserved sites are less likely to become ineffective due to drug resistance in 
the future.   
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